Projected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects

American Heart Journal

Volumn 161, Issue 4, 2011, Pages 719-725

  Muntner, Paul ^a   Mann, Devin ^b   Wildman, Rachel P ^c   Shimbo, Daichi ^d   Fuster, Valentin ^b,e   Woodward, Mark ^f  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^f UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG USE; FEMALE; HEALTH SURVEY; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); PILL; POLYPILL; PRIORITY JOURNAL; RISK REDUCTION; STROKE; UNSPECIFIED SIDE EFFECT;

CARDIOVASCULAR DISEASES; DRUG COMBINATIONS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; QUESTIONNAIRES; RISK FACTORS;

EID: 79953715356     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2010.12.019     Document Type: Article

References (29)

1. World Health Organization. Secondary prevention of non-communicable disease in low and middle income countries through community-based and health service interventions. (WHO-Wellcome Trust meeting report 1-3.). 2002. Geneva.
2. Wald N.J., and Law M.R. A strategy to reduce cardiovascular disease by more than 80% BMJ 326 2003 1419
3. Rodgers A. A cure for cardiovascular disease? Combination treatment has enormous potential, especially in developing countries BMJ 326 2003 1407 1408
4. Watts G. What happened to the polypill? BMJ 337 2008 a1822
5. Fuster V., and Sanz G. A polypill for secondary prevention: time to move from intellectual debate to action Nat Clin Pract Cardiovasc Med 4 2007 173 (Pubitemid 46502085)
6. National Center for Health Statistics NHANES design and conduct http://www.cdcgov/nchs/about/major/nhanes/ 2008. [accessed 2008 Nov. 19]
7. Perloff D., Grim C.E., and Flack J.M. Human blood pressure determination by sphygmomanometry Circulation 88 1993 2460 2470
8. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
9. Mosca L. Aspirin chemoprevention: one size does not fit all Circulation 117 2008 2844 2846 (Pubitemid 351787056)
10. Smith S.C. Jr., Allen J., and Blair S.N. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute Circulation 113 2006 2363 2372 (Pubitemid 43947981)
11. Lonn E., Bosch J., and Teo K.K. The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions Circulation 122 2010 2078 2088
12. Psaty B.M., Lumley T., and Furberg C.D. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis JAMA 289 2003 2534 2544 (Pubitemid 37430155)
13. Baigent C., Blackwell L., and Collins R. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 373 2009 1849 1860
14. O'Regan C., Wu P., and Arora P. Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients Am J Med 121 2008 24 33
15. Ward S., Lloyd J.M., and Pandor A. A systematic review and economic evaluation of statins for the prevention of coronary events Health Technol Assess 11 2007 1 iv
16. Bradley H.A., Wiysonge C.S., and Volmink J.A. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis J Hypertens 24 2006 2131 2141 (Pubitemid 44611017)
17. Wiysonge C.S., Bradley H., and Mayosi B.M. Beta-blockers for hypertension Cochrane Database Syst Rev 2007 CD002003
18. Neal B., MacMahon S., and Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood- pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration Lancet 356 2000 1955 1964
19. Law M.R., Wald N.J., and Morris J.K. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials BMJ 326 2003 1427
20. Law M.R., Wald N.J., and Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis BMJ 326 2003 1423
21. Kannel W.B., Feinleib M., and McNamara P.M. An investigation of coronary heart disease in families. The Framingham offspring study Am J Epidemiol 110 1979 281 290 (Pubitemid 10204328)
22. The ARIC Study Investigators The decline of ischaemic heart disease mortality in the ARIC study communities Int J Epidemiol 18 1989 S88 S98
23. Fried L.P., Borhani N.O., and Enright P. The Cardiovascular Health Study: design and rationale Ann Epidemiol 1 1991 263 276
24. Yusuf S., Pais P., and Afzal R. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial Lancet 373 2009 1341 1351
25. Patel A., Shah T., and Shah G. Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (Polycap): a five-arm phase I crossover trial in healthy volunteers Am J Cardiovasc Drugs 10 2010 95 103
26. Gaziano T.A., Opie L.H., and Weinstein M.C. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis Lancet 368 2006 679 686
27. Vos T., Carter R., and Barendregt J. Assessing cost-effectiveness in prevention (ACE-Prevention): final report 2010 University of Queensland, Brisbane and Deakin University Melbourne
28. Ogedegbe G., Harrison M., and Robbins L. Barriers and facilitators of medication adherence in hypertensive African Americans: a qualitative study Ethn Dis 14 2004 3 12 (Pubitemid 38262740)
29. Haynes R.B., McDonald H.P., and Garg A.X. Helping patients follow prescribed treatment: clinical applications JAMA 288 2002 2880 2883 (Pubitemid 35425074)